


1. An inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, a hydroxyformamidine derivative represented by the formula:



wherein R¹ to R⁵ are identical or different and represent a hydrogen atom; a hydroxyl group; a carboxyl group; a halogen atom; a C₁₋₁₄ alkyl group; a C₁₋₁₄ alkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkenyl group; a C₁₋₆ alkoxy C₁₋₆ alkyl group; a C₃₋₈ cycloalkyl C₁₋₆ alkyl group; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a mono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N-(N', N'-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a nitro group; a thiol group; a phenoxy group; a phenoxy group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and halogen atoms; a phenylthio group; a nitrophenylthio group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ alkylthio wherein the benzene ring is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3

substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α -cyanobenzyl group; an α -cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo[2.2.1]-hept-5-en-2,3-dicarboxyimidyl group; a benzoyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)amino alkyl groups; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a phenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxy carbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; a group represented by the formula: $-Y-(CR^{61}R^{62})_m-(CR^{63}R^{64})_n-R^7$ [wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a

Sub
B1

00860403-062204

[illegible]

Sub B¹

alkyl)amino group; a C₂₋₆ alkoxy carbonyl group; or a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6]; or a group represented by the formula: -SO₂NR⁸R⁹ [wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperadino group, a pyrrolidinyl group, a piperidino group, or a morpholino group], or alternatively,

the two groups adjacent to each other of R¹ to R⁵, taken together with the benzene ring to which they are bonded, form a phthalimide ring; a phthalimide ring substituted with a C₁₋₆ alkyl group; an indole ring; an indane ring; an indazole ring; a benzotriazole ring; an S,S-dioxobenzothiophene ring; a

2,3-dihydroimidazo[2,1-b]benzothiazole ring; a dibenzofuran ring; a dibenzofuran ring substituted with a C₁₋₆ alkoxy group; a fluorene ring; a fluorene ring substituted with a halogen atom; a pyrene ring; a carbostyryl ring; a carbostyryl ring substituted with a C₁₋₆ alkyl group; a naphthalene ring; a naphthalene ring substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, nitro groups, and C₁₋₆ alkyl groups; a 1,2,3,4-tetrahydronaphthalene ring; a quinoline ring; a quinoline ring substituted with a C₁₋₆ alkyl group; an isoquinoline ring; a 2-oxo- α -chromene ring; a 2-oxo- α -chromene ring substituted with 1 to 3 substituents selected from the group

[illegible]

2. The inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, a hydroxyformamidine derivative, according to Claim 1, wherein R¹ to R⁵ are identical or different and represent a hydrogen atom; a hydroxyl group; a carboxyl group; a halogen atom; a C₁₋₁₄ alkyl group; a C₁₋₁₄ alkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a mono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N-(N',N'-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a nitro group; a thiol group; a phenoxy group; a phenoxy group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and halogen atoms; a phenylthio group; a nitrophenylthio group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ alkylthio group wherein the benzene ring is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α -cyanobenzyl group; an α -cyanobenzyl group

substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo[2.2.1]-hept-5-en-2,3-dicarboxyimidyl group; a benzoyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl) amino alkyl groups; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a phenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxy carbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; or a group represented by the formula: -Y-(CR⁶¹R⁶²)_m-(CR⁶³R⁶⁴)_n-R⁷ [wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷ represents a hydrogen atom; a halogen atom; a C₁₋₁₄ alkyl group; a C₃₋₈ cycloalkyl group; a C₂₋₁₀ alkenyl group; a C₂₋₆ alkynyl group;


a phenyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxy groups, phenethyl groups, C₂₋₆ alkoxy carbonyl groups, and halogen atoms; a cyano group; a carboxyl group; a C₁₋₆ alkoxy group; a C₁₋₆ hydroxyalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkylthio group; a C₂₋₆ alkanoyloxy group; a C₂₋₆ alkanoyloxy C₁₋₆ alkyl group; a phenoxy group; a phenylthio group; an N-(C₁₋₆ alkyl)toluidino group; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group substituted with a C₁₋₆ alkoxy group; a pyrrolidino group substituted with a C₁₋₆ alkyl group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperadiny group; a piperadin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidiny group; a homopiperidiny group substituted with a C₁₋₆ alkyl group; a pyridylthio group; a quinolyl group; a furyl group; an oxetanyl group; an oxolanyl group; a dioxolanyl group; a dioxolanyl group substituted with a C₁₋₆ alkyl group; an oxanyl group; a dioxanyl group; a dioxanyl group substituted with a C₁₋₆ alkyl group; a benzodioxanyl group; a pyrrolidon-1-yl group; a pyrrolidinyl group; an N-(C₁₋₆ alkyl)pyrrolidinyl group; a piperidinyl group; an N-(C₁₋₆ alkyl)piperidinyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a 2,6-purindion-7-yl group substituted with C₁₋₆ alkyl group(s); a furfuryl group; a di(C₁₋₆ alkyl)amino group; a C₂₋₆ alkoxy carbonyl group; or a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6], or a

pharmaceutically-acceptable salt thereof.

3. The inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, a hydroxyformamidine derivative or a pharmaceutically-acceptable salt thereof, according to Claim 2, wherein R^1 , R^2 , R^4 , and R^5 represent hydrogen atoms.

4. The inhibitor for production of 20-hydroxyeicosatetraenoic acid, according to any one of Claims 1 to 3, which is a therapeutic agent for kidney diseases, cerebrovascular diseases, or circulatory diseases.

5. A hydroxyformamidine derivative represented by the formula:



wherein at least one of R^{11} to R^{55} represents a C_{5-14} alkyl group; a C_{2-6} alkenyl group; a C_{3-8} cycloalkyl C_{1-6} alkyl group; a C_{2-6} alkynyl group; a C_{3-8} cycloalkyl group; a C_{3-8} cycloalkoxy group; a C_{2-10} alkanoyl group; a C_{1-6} hydroxyalkyl group; a C_{1-6} hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C_{2-6} alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C_{2-6} alkoxycarbonyl C_{1-6} alkyl group; a di(C_{1-6} alkyl)amino C_{2-6} alkoxycarbonyl group; a mono- or di(C_{1-6} alkyl)amino group; a C_{2-10} alkanoylamino group; a C_{2-6} alkanoylamino group substituted with a C_{1-6} alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C_{1-6} alkyl or phenyl groups; an N-(N' , N' -di(C_{1-6} alkyl)amino C_{1-6} alkyl) carbamoyl group; a cyano group; a cyano C_{1-6} alkyl group; a C_{1-6} alkylsulfonyl group; a phenylsulfonyl group; a C_{1-6} alkylthio C_{1-6} alkyl group; a phenylsulfonyl C_{1-6} alkylthio group wherein the benzene ring is

substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a bicyclo[2.2.1]-hept-5-en-2,3-dicarboxyimidyl group; a benzoyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)amino alkyl groups; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a phenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxy carbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; a group represented by the formula: -Y-(CR⁶¹R⁶²)_m-(CR⁶³R⁶⁴)_n-R⁷⁷ [wherein Y represents an oxygen or sulfur

Sub
A9
cont

[illegible]

Sub
A9
cont

alkyl groups; a 2,6-purindion-7-yl group substituted with at least one C₁₋₆ alkyl group; a furfuryl group; a di(C₁₋₆ alkyl) amino group; a C₂₋₆ alkoxy carbonyl group; or a di(C₁₋₆ alkyl) amino C₁₋₆ alkoxy group; m is an integer of 1 to 6; and n is an integer of 0 to 6]; or a group represented by the formula: -SO₂NR⁸R⁹ [wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperadino group, a pyrrolidinyl group, a piperidino group, or a morpholino group], or alternatively,

the two groups adjacent to each other of R¹¹ to R⁵⁵, taken together with the benzene ring to which they are bonded, form a phthalimide ring; a phthalimide ring substituted with a C₁₋₆ alkyl group; an indole ring; an indane ring; an indazole ring; a benzotriazole ring; an S,S-dioxobenzothiophene ring; a 2,3-dihydroimidazo[2,1-b]benzothiazole ring; a dibenzofuran ring; a dibenzofuran ring substituted with a C₁₋₆ alkoxy group; a fluorene ring; a fluorene ring substituted with a halogen atom; a pyrene ring; a carbostyryl ring; a carbostyryl ring substituted with a C₁₋₆ alkyl group; a naphthalene ring; a naphthalene ring substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, nitro groups, and C₁₋₆ alkyl groups; a 1,2,3,4-tetrahydronaphthalene ring; a quinoline ring; a quinoline ring substituted with a C₁₋₆ alkyl group; an

Sub
A9
Cont

isoquinoline ring; a 2-oxo- α -chromene ring; a 2-oxo- α -chromene ring substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, and C₁₋₆ alkoxy C₁₋₆ alkyl groups; a cinnolin ring; a cinnolin ring substituted with a C₁₋₆ alkyl group; a phthalazindione ring; a benzothiazol ring; a benzothiazol ring substituted with a C₁₋₆ alkyl group; a benzodioxorane ring; and a benzobutyrolactone ring, and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom, or a pharmaceutically-acceptable salt thereof.

Sub
B3

6. The hydroxyformamidine derivative or a pharmaceutically-acceptable salt thereof, according to Claim 5, wherein at least one of R¹¹ to R⁵⁵ represents a C₅₋₁₄ alkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxy carbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxy carbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxy carbonyl group; a mono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a benzoylamino group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N-(N', N'-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl) carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenylsulfonyl C₁₋₆ alkylthio group wherein the benzene ring is substituted with 1 to 5 halogen atoms; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α -cyanobenzyl group; an α -cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzyl group substituted with a

bicyclo[2.2.1]-hept-5-en-2,3-dicarboxyimidyl group; a benzoyl group; a styryl group; a styryl group substituted with 1 to 5 substituents selected from the group consisting of C₁₋₆ alkoxy groups and di(C₁₋₆ alkyl)amino alkyl groups; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a phthalimidoyl group; a phthalimidoyl group substituted with 1 to 3 halogen atoms; an N-carbazolyl group; a dioxopiperidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups; a phenylsulfonylamino group; a phenylsulfonylamino group substituted with 1 to 3 C₁₋₆ alkyl groups; a C₁₋₆ alkylaminosulfonyl C₁₋₆ alkyl group; a thiadiazolyl group; an oxadiazolyl group; an oxadiazolyl group substituted with a substituted phenyl group wherein the substituents in the substituted phenyl group are 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxy carbonyl groups; a thienopyrimidinylthio group; a thienopyrimidinylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a thienopyridylthio group; a thienopyridylthio group substituted with 1 to 3 C₁₋₆ alkyl groups; a benzothiazolylthio group; a benzothiazolylthio group substituted with 1 to 3 halogen atoms; or a group represented by the formula: -SO₂NR⁸R⁹ [wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups,

Sub
B3

7. The hydroxyformamidine derivative or a

pharmaceutically-acceptable salt thereof, according to Claim 6, wherein at least one of R¹¹ to R⁵⁵ represents a C₅₋₁₄ alkyl group; a C₂₋₆ alkynyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₂₋₁₀ alkanoyl group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆ hydroxyalkyl group substituted with 1 to 6 halogen atoms; a C₂₋₆ alkoxycarbonyl group; a 3-phenyl-2-propenyloxycarbonyl group; a C₂₋₆ alkoxycarbonyl C₁₋₆ alkyl group; a di(C₁₋₆ alkyl)amino C₂₋₆ alkoxycarbonyl group; a mono- or di(C₁₋₆ alkyl)amino group; a C₂₋₁₀ alkanoylamino group; a C₂₋₆ alkanoylamino group substituted with a C₁₋₆ alkyl group; a carbamoyl group; a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl or phenyl groups; an N-(N', N'-di(C₁₋₆ alkyl)amino C₁₋₆ alkyl)carbamoyl group; a cyano group; a cyano C₁₋₆ alkyl group; a C₁₋₆ alkylsulfonyl group; a phenylsulfonyl group; a C₁₋₆ alkylthio C₁₋₆ alkyl group; a phenyl group; a benzyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of cyano groups, halogen atoms, C₁₋₆ alkyl groups, and C₁₋₆ alkoxy groups; a biphenyl group; an α-cyanobenzyl group; an α-cyanobenzyl group substituted with 1 to 5 halogen atoms; a benzoyl group; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyrimidinyl group; a pyrimidinyl group substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl groups and C₁₋₆ alkoxy groups; a pyrrolidinyl group; a pyrazolyl group; a pyrazolyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and trifluoromethyl groups; a furyl group; a furyl group substituted with 1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkyl groups, and C₂₋₆ alkoxycarbonyl groups; or a group represented by the formula: -SO₂NR⁸R⁹ [wherein R⁸ and R⁹ are identical or different and represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₆ alkanoyl group, an isoxazolyl group, an isoxazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiadiazolyl group, a thiadiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a thiazolyl group, a thiazolyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyridyl

Sub B3
 group, a pyridyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkyl groups, a pyrimidinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, a pyridazinyl group, a pyridazinyl group substituted with 1 to 3 C₁₋₆ alkoxy groups, an indazolyl group, or a carbamoyl group mono- or di-substituted with C₁₋₆ alkyl groups, or alternatively, taken together with the nitrogen atom to which they are bonded, form a 3,5-dioxopiperadino group, a pyrrolidinyl group, a piperidino group, or a morpholino group] and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.

8. The hydroxyformamidine derivative or a pharmaceutically-acceptable salt thereof, according to Claim 5, wherein at least one of R¹¹ to R⁵⁵ represents a group represented by the formula: $-Y-(CR^{61}R^{62})_m-(CR^{63}R^{64})_n-R^{77}$ [wherein Y represents an oxygen or sulfur atom; R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷⁷ represents a halogen atom; a C₄₋₁₄ alkyl group; a C₃₋₈ cycloalkyl group; a C₂₋₁₀ alkenyl group; a C₂₋₆ alkynyl group; a phenyl group; a phenyl group substituted with 1 to 3 substituents selected from the group consisting of nitro groups, cyano groups, C₁₋₆ alkyl groups, C₁₋₆ alkoxy groups, C₁₋₆ alkylthio groups, phenyl groups, phenoxy groups, phenethyl groups, C₂₋₆ alkoxy carbonyl groups, and halogen atoms; a cyano group; a carboxyl group; a C₁₋₆ alkoxy group; a C₁₋₆ hydroxyalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkoxy C₁₋₆ alkoxy C₁₋₆ alkoxy group; a C₁₋₆ alkylthio group; a C₂₋₆ alkanoyloxy group; a C₂₋₆ alkanoyloxy C₁₋₆ alkyl group; a phenoxy group; a phenylthio group; an N-(C₁₋₆ alkyl) toluidino group; a pyrrolidino group; a piperidino group; a morpholino group; a pyridyl group; a pyridyl group substituted with a C₁₋₆ alkyl group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group substituted

Figure 1 consists of 12 micrographs arranged in a 4x3 grid, illustrating the stages of chick embryo development. The first row shows the fertilized egg, cleavage stages, and gastrulation. The second row shows neurulation, somite formation, and limb bud development. The third row shows the development of the head, tail, and internal organs. The fourth row shows the hatching process and the newly hatched chick.

9. The hydroxyformamidine derivative or a pharmaceutically-acceptable salt thereof, according to Claim 8, wherein at least one of R¹¹ to R⁵⁵ represents a group represented by the formula: -O-(CR⁶¹R⁶²)_m-(CR⁶³R⁶⁴)_n-R⁷⁷ [wherein R⁶¹, R⁶², R⁶³, and R⁶⁴ are identical or different and represent a hydrogen atom, a halogen atom, a C₁₋₄ alkyl group, or a trifluoromethyl group; R⁷⁷ represents a di(C₁₋₆ alkyl)amino group; a di(C₁₋₆ alkyl)amino C₁₋₆ alkoxy group; a piperidyl group; a piperidinyl group substituted

with a C₁₋₆ alkyl group; a piperidino group; a piperidino group substituted with a C₁₋₆ alkyl group; a pyridyl group; a pyridinyl group substituted with a C₁₋₆ alkyl group; a pyridinyl group substituted with a C₁₋₆ alkoxy group; a pyridylthio group; a pyrrolidino group; a pyrrolidino group substituted with a C₁₋₆ alkyl group; a pyrrolidone-1-yl group; a pyrrolidinyl group; a pyrrolidinyl group substituted with a C₁₋₆ alkyl group; a pyrrolyl group; a thienyl group; a thiazolyl group; a morpholino group; a morpholino group substituted with a C₁₋₆ alkyl group; a morpholinyl group; a morpholinyl group substituted with a C₁₋₆ alkyl group; a homomorpholinyl group; a thiomorpholino group; a thiomorpholino group substituted with a C₁₋₆ alkyl group; a thiomorpholinyl group; a thiomorpholinyl group substituted with a C₁₋₆ alkyl group; a piperadiny group; a piperadin-1-yl group substituted with a C₁₋₆ alkyl group at the 4-position; a homopiperidinyl group; or a homopiperidinyl group substituted with a C₁₋₆ alkyl group; m is an integer of 1 to 6; and n is an integer of 0 to 6], and the remaining groups of R¹¹ to R⁵⁵ are identical or different and represent a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a trifluoromethyl group, a nitro group, or a halogen atom.

10. The hydroxyformamide derivative or a pharmaceutically-acceptable salt thereof, according to any one of Claims 7 to 9, wherein R¹¹, R²², R⁴⁴, and R⁵⁵ represent hydrogen atoms.

11. An inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, the hydroxyformamide derivative or a pharmaceutically-acceptable salt thereof according to any one of Claims 5 to 10.

12. The inhibitor for production of 20-hydroxyeicosatetraenoic acid, according to Claim 11, which is

Sub
B4 - a therapeutic agent for kidney diseases, cerebrovascular diseases,
or circulatory diseases.

add
B5

add
D1

00669103-062204
T02290-00169860